Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76:681–93.

Article  PubMed  Google Scholar 

Vitale A, Trevisani F, Farinati F, Cillo U. Treatment of hepatocellular carcinoma in the precision medicine era: from treatment stage migration to therapeutic hierarchy. Hepatology. 2020;72:2206–18.

Article  PubMed  Google Scholar 

Choi JW, Kim HC, Lee JH, et al. Transarterial chemoembolization of hepatocellular carcinoma with segmental portal vein tumour thrombus. Eur Radiol. 2017;27:1448–58.

Article  PubMed  Google Scholar 

Hwang H, Kim JH, Ko E, et al. Chemoembolization as First-Line treatment for hepatocellular carcinoma invading segmental portal vein with tumor burden limited to a monosegmental level. Br J Radiol. 2024. https://doi.org/10.1093/bjr/tqae052.

Article  PubMed  Google Scholar 

Salem R, Gordon AC, Mouli S, et al. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2016;151(1155–63): e2.

Google Scholar 

Spreafico C, Sposito C, Vaiani M, et al. Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion. J Hepatol. 2018;68:724–32.

Article  PubMed  Google Scholar 

Abouchaleh N, Gabr A, Ali R, et al. (90)Y radioembolization for locally advanced hepatocellular carcinoma with portal vein thrombosis: long-term outcomes in a 185-patient cohort. J Nucl Med. 2018;59:1042–8.

Article  PubMed  Google Scholar 

Vilgrain V, Pereira H, Assenat E, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017;18:1624–36.

Article  PubMed  Google Scholar 

Chow PKH, Gandhi M, Tan SB, et al. SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma. J Clin Oncol. 2018;36:1913–21.

Article  PubMed  Google Scholar 

Garin E, Tselikas L, Guiu B, et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6:17–29.

Article  PubMed  Google Scholar 

Hermann AL, Dieudonne A, Ronot M, et al. Relationship of tumor radiation-absorbed dose to survival and response in hepatocellular carcinoma treated with transarterial radioembolization with (90)Y in the SARAH study. Radiology. 2020;296:673–84.

Article  PubMed  Google Scholar 

Salem R, Johnson GE, Kim E, et al. Yttrium-90 radioembolization for the treatment of solitary unresectable HCC: the LEGACY study. Hepatology. 2021;74:2342–52.

Article  PubMed  Google Scholar 

Kim E, Sher A, Abboud G, et al. Radiation segmentectomy for curative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): a single-centre, single-arm study. Lancet Gastroenterol Hepatol. 2022;7:843–50.

Article  PubMed  Google Scholar 

Chernyak V, Fowler KJ, Kamaya A, et al. Liver imaging reporting and data system (LI-RADS) version 2018: imaging of hepatocellular carcinoma in at-risk patients. Radiology. 2018;289:816–30.

Article  PubMed  Google Scholar 

Choi JW, Lee JM, Kim HC, et al. Iatrogenic arterioportal fistula caused by radiofrequency ablation of hepatocellular carcinoma: clinical course and treatment outcomes. J Vasc Interv Radiol. 2020;31:728–36.

Article  PubMed  Google Scholar 

Choi JW, Suh M, Paeng JC, Kim JH, Kim HC. Radiation major hepatectomy using ablative dose Yttrium-90 radioembolization in patients with hepatocellular carcinoma 5 cm or larger. J Vasc Interv Radiol. 2024;35:203–12.

Article  PubMed  Google Scholar 

Salem R, Padia SA, Lam M, et al. Clinical, dosimetric, and reporting considerations for Y-90 glass microspheres in hepatocellular carcinoma: updated 2022 recommendations from an international multidisciplinary working group. Eur J Nucl Med Mol Imaging. 2023;50:328–43.

Article  PubMed  Google Scholar 

Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52–60.

Article  PubMed  Google Scholar 

Garin E, Tselikas L, Guiu B, et al. Long-term overall survival after selective internal radiation therapy for locally advanced hepatocellular carcinomas: updated analysis of DOSISPHERE-01 Trial. J Nucl Med. 2024;65:264–9.

Article  PubMed  PubMed Central  Google Scholar 

Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894–905.

Article  PubMed  Google Scholar 

Yoon SM, Ryoo BY, Lee SJ, et al. Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: a randomized clinical trial. JAMA Oncol. 2018;4:661–9.

Article  PubMed  PubMed Central  Google Scholar 

He M, Li Q, Zou R, et al. Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial. JAMA Oncol. 2019;5:953–60.

Article  PubMed  PubMed Central  Google Scholar 

Kim TS, Yang K, Choi GH, et al. Surgical outcome and risk scoring to predict survival after hepatic resection for hepatocellular carcinoma with portal vein tumor thrombosis. Ann Hepatobiliary Pancreat Surg. 2024;28:134–43.

Article  PubMed  PubMed Central  Google Scholar